Bio affinity company BAC has appointed Dr Andrew Carr as chairman to its supervisory board. Dr Carr brings experience in the biotech industry to the role.
As ceo of Amersham Biosciences and a director of Amersham, Carr played a key role in growing the life science research and bio-separations business units until GE Healthcare acquired Amersham in 2004.
Carr said: "BAC's technology has important proven applications in the manufacture of bio molecules which have now been adopted by many of the world's leading bio-pharmaceutical companies, and I am delighted to be invited to lead the Supervisory Board at this exciting stage of the company's growth and selection of strategic options."
Carr is chairman of deltaDOT and Teraview, a director of SciBridge and an advisor to SpinX-Technologies SA.